Sign in
Taking peoplePhase 3

Ketosteril to help prevent muscle and nutrition loss in nephrotic syndrome

Tests Ketosteril for preventing protein-energy wasting in adults with nephrotic syndrome.

Key facts

Who runs it
Military Institute od Medicine National Research Institute
Where
Poland8 sites in 1 countryChoose a country to see its sites
Registry title
Ketoanalogues for Muscle Mass Loss in Nephrotic Syndrome
Status
Recruiting
Phase
Phase 3
People taking part
150 people, planned
Started
3 Jan 2023
Expected to end
31 Aug 2027
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Ketosteril
  • Medium Protein Diet (MPD)
Record updated
8 February 2023

Who can take part

The trial is looking for adults with nephrotic syndrome, newly found or come back, to test Ketosteril with a medium protein diet against the diet alone. The aim is to prevent loss of muscle and body stores.

Age
18 Years and older
Sex
All
Disease stage
Nephrotic syndrome, new diagnosis or relapse. Kidney filtration (GFR) must be 30 mL/min/1.73m2 or higher. A relapse means proteinuria under 2.0 g/day or uPCR under 2000 mg/g in the 6 months before.
Earlier treatment
For a relapse: prednison dose of 10 mg/day or less in the last 3 months before it. No Ketosteril in the last 1 year.
Biomarker or test result
Serum albumin below 3.0 g/dL and protein in the urine over 3.5 g/day or over 50 mg/kg.
Main reasons for not taking part
  • Kidney disease from diabetes, HbA1c >7% (53 mmol/mol), lupus or small vessel vasculitis
  • Positive ANA, anti-dsDNA or ANCA, HIV, hepatitis C or HBsAg tests
  • Pregnancy, cancer or monoclonal gammopathy
  • Body mass index of 40 kg/m2 or more
  • Other clinical trial or Ketosteril use in the last 1 year
Show the full registry criteria (19)Hide the full registry criteria

Who can take part

  • Nephrotic syndrome with serum albumin < 3.0 g/dL and daily proteinuria of > 3.5 g/day or > 50 mg/kg
  • New diagnosis or relapse of nephrotic syndrome (defined as: proteinuria of < 2.0 g/day or uPCR < 2000 mg/g in the last 6 months prior to relapse and prednison dose equal to or less than 10 mg/day in the last 3 months prior relapse)
  • Glomerular filtration rate qual to or higher than 30 mL/min/1.73m2 based on Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation

Who cannot take part

  • Positive antinuclear antibodies, anti-dsDNA or antineutrophil cytoplasmic antibodies (ANCA)
  • Alcohol or drug abuse
  • Participation in other clinical trial or the use of Ketosteril in the last 1 year prior to screening
  • Diabetic kidney disease
  • Positive anti-HIV or anti-hepatitis C antibodies, HBsAg
  • Severe acute or chronic disease affecting nutritional status
  • Mental disorders
  • Failure to comply with medical recommendations, lack of cooperation
  • HbA1c >7%
  • Small vessels vasculitis
  • Systemic lupus erythematosus
  • Monoclonal gammopathy
  • Pregnancy
  • Body mass index >= 40 kg/m2
  • Neoplasm
  • Contraindication to Ketosteril

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age
  • Nephrotic syndrome

This trial is currently available in Poland.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this non-commercial clinical trial is to assess efficacy and safety of ketoanalogues of essential amino acids in the prevention of protein-energy wasting in nephrotic syndrome.

The 2 groups in the trial

  • KA+MPDTreatment being tested

    Ketosteril + Medium Protein Diet (MPD) for 12 months

    Treatment: Ketosteril and Medium Protein Diet (MPD)

  • MPDExisting treatment, for comparison

    Medium Protein Diet (MPD) for 12 months

    Treatment: Medium Protein Diet (MPD)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
FORMA - a Multicenter Randomized-controlled Trial to Evaluate the Efficacy and Safety of Ketoanalogues of Essential Amino Acids in Prophylaxis of Protein-energy Wasting in Nephrotic Syndrome
Plain-language title
Ketosteril to help prevent muscle and nutrition loss in nephrotic syndromeGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 15 November 2026.
Criteria questions
Built from NCT05716880, who can take part
Record updated
8 February 2023